|Chemical and physical data|
|Molar mass||439.53 g·mol−1|
|3D model (JSmol)|
Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II and III clinical trials.
- Zheng X, Gao L, Wang L, Liang C, Wang B, Liu Y, et al. (July 2019). "Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor". Journal of Medicinal Chemistry. 62 (13): 6003–6014. doi:10.1021/acs.jmedchem.9b00654. PMID 31194544.
- Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (July 2019). "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research. 167: 45–67. doi:10.1016/j.antiviral.2019.04.006. PMC 7132446. PMID 30974127.
- Taylor, Nick Paul (7 April 2022). "ArkBio's ex-Roche antiviral hits primary goal in RSV phase 3, sparking race to regulator and wait for more data". Fierce Biotech. Retrieved 17 July 2022.